Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Stock Short Interest Report for October

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) saw a large drop in short interest during the month of October. As of October 30th, there was short interest totaling 184,372 shares, a drop of 77.5% from the October 15th total of 818,602 shares. Based on an average daily volume of 7,649,526 shares, the short-interest ratio is presently 0.0 days. Approximately 6.6% of the shares of the stock are sold short.

Alaunos Therapeutics Stock Down 0.6%

Shares of TCRT stock opened at $1.60 on Thursday. Alaunos Therapeutics has a twelve month low of $0.72 and a twelve month high of $4.50. The stock’s fifty day simple moving average is $1.64 and its 200 day simple moving average is $2.29. The firm has a market capitalization of $5.31 million, a P/E ratio of -0.84 and a beta of -1.02.

Alaunos Therapeutics (NASDAQ:TCRT) last posted its earnings results on Friday, August 14th. The company reported ($0.41) EPS for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Alaunos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, Alaunos Therapeutics has an average rating of “Sell”.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc. is a biotechnology company focused on developing genetically engineered T-cell therapies for cancer. The company has concentrated on T-cell receptor (TCR) therapies designed to recognize and attack tumor-specific mutations, with an emphasis on treating solid tumors that can be difficult to address with conventional immunotherapies. The company’s research platform has included the Sleeping Beauty gene-transfer system, a nonviral technology intended to introduce therapeutic T-cell receptors into a patient’s own T cells.